Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Antibody Engineering & Therapeutics Europe
1 - 3 June, 2027
Congress CenterBasel Switzerland

Ulrich Brinkmann
Expert Scientist and Scientific Director at Roche Innovation Center Munich
Speaker

Profile

Dr. Ulrich Brinkmann is a member of Roche’s Large Molecule Research organization within Pharma Research & Early Development at the Roche Innovation Center Munich (Penzberg, Germany). His work focuses on protein & antibody engineering, bispecifics, and on delivery platforms for targeted payload delivery. Prior to joining Roche, he served as CSO in functional genomics and pharmacogenetics companies Xantos and Epidauros. His early work in the Molecular Biology Lab of Ira Pastan at the NIH/NCI focused on antibody stabilization and engineering technologies, and on generating recombinant immunotoxins for cancer therapy. Dr. Brinkmann is author of numerous publications and inventor of many patents covering recombinant antibodies, pharmaco- & functional genomics, immunotoxins and protein engineering technologies and applications.

Agenda Sessions

  • Conditional Activation of Targeted Multifunctional Antibody Derivatives Based on Antibody Chain Exchange/Complementation Approaches

    13:45